Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.

doi:10.5604/16652681.1222098

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.

Annals of hepatology - 1 Jan 2000

Rodriguez-Torres Maribel, Lawitz Eric, Yangco Bienvenido, Jeffers Lennox, Han Steven-Huy, Thuluvath Paul J, Rustgi Vinod, Harrison Stephen, Ghalib Reem, Vierling John M, Luketic Velimir, Zamor Philippe J, Ravendhran Natarajan, Morgan Timothy R, Pearlman Brian, O'Brien Christopher, Khallafi Hicham, Pyrsopoulos Nikolaos, Kong George, McPhee Fiona, Yin Philip D, Hughes Eric, Treitel Michelle

Abstract excerpt

Background. Patient race and ethnicity have historically impacted HCV treatment response. This phase 3 study evaluated daclatasvir with peginterferon-alfa-2a/ribavirin (pegIFN alfa-2a/RBV) in treatment-naive black/African American (AA), Latino, and white non-Latino patients with chronic HCV genotype 1 infection. MATERIAL AND METHODS: In this single-arm, open-label study, 246 patients received daclatasvir plus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbamates

Share to Hispanic or Latino

Share to Imidazoles

Share to Polyethylene Glycols

Share to Puerto Rico

Share to Pyrrolidines

Share to Valine

Source

Open in PubMed

Identifiers

PMID: 27740516
DOI: 10.5604/16652681.1222098

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.PMID 27740516Read ↗

Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials.Semantic proximity Read ↗

Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity.Semantic proximity Read ↗

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.Semantic proximity Read ↗

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.Semantic proximity Read ↗

Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.Semantic proximity Read ↗

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.Semantic proximity Read ↗

Direct acting antivirals for the treatment of hepatitis C in ethnic minority populations.Semantic proximity Read ↗

Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.Semantic proximity Read ↗

Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic.Semantic proximity Read ↗

Boceprevir for untreated chronic HCV genotype 1 infection.Semantic proximity Read ↗

Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*.Semantic proximity Read ↗

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.